The AstraZeneca laboratory was able to use “obsolete” data during its clinical trials in the United States on the vaccine against Kovid-19, according to a statement released Monday evening by an American institution.
A monitoring group “expressed concern that AstraZeneca may have used outdated information in this test” in the United States, “which could result in an incomplete estimate of effectiveness”, said the National Institute of Infectious Diseases and Allergy (NIAID), which oversees clinical trials of vaccines.
“We urge working with the Data Safety and Security Monitoring Board (DSMB) to assess the effectiveness of the data and to ensure that the most accurate, recent and most effective possible is delivered as soon as possible. Go public soon “, he said in a press release.
The AstraZeneca laboratory defended its vaccine on Monday, rejected by a large proportion of Europeans, claiming it was 80% effective against Kovid in the elderly and undergoing Phase III clinical trials in the United States. Later, the risk of clotting did not increase. 32,449 participants.
The Swedish-British AstraZeneca vaccine is 79% effective at preventing symptomatic Kovid-19 in the general clinical population and 100% at preventing severe forms of illness and hospitalization, after these clinical trials were added to the laboratory .
This month many countries have suspended their use for fear that it may be fatal at times. On Thursday, the European Medicine Agency (EMA) has so far considered it “safe and effective” and has begun using the vaccine again in some countries.